Navigation Links
Cempra Pharmaceuticals to Present at the 2011 Wells Fargo Healthcare Conference
Date:6/22/2011

CHAPEL HILL, N.C., June 22, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, president and chief executive officer, will present at the 2011 Wells Fargo Healthcare Conference at 1 p.m. EDT, June 23, 2011, in Boston.  Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and other infections and TAKSTA™ for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.

Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
Russo Partners LLC
(212) 845-4251
Tony.russo@russopartnersllc.com


'/>"/>
SOURCE Cempra Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Cempra Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
2. Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris
3. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
4. Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
5. Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
7. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
8. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
9. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
10. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
11. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Germany und LONDON ... , Ziel der Zusammenarbeit sind ... genomischer Daten aus Plasmaproben zur Steuerung von Therapien ... werden kann  Neuer Bluttest basiert auf ... und soll auf Rotor-Gene Q, einer Automationsplattform der ...
(Date:7/28/2014)... 2014 OmPrompt today announces ... help it meet the global demand for customer ... logistics. Albion joins Shackleton Ventures.      ... the past 18 months OmPrompt has underpinned accelerated ... team and its operations. The new funding will ...
(Date:7/25/2014)... N.C. , July 25, 2014  In today,s ... is costly and challenging - as is managing a ... Is it possible - or even preferable ... If so, where can you combine resources and activities, ... These are just a few of ...
Breaking Medicine Technology:QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7OmPrompt Funded for Customer Automation Management Market Expansion 2Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2
... April 11, 2011 iCyt Mission Technology, Inc. (iCyt), ... announced the introduction of its new line of 405nm-excited ... Violet™ 421 products are part of the first commercial ... "This exciting new class of fluorescent probes will ...
... 11, 2011 Leading-edge Clinical Pharmacology and Cardiac ... announces the addition of Aziz Karim, BPharm, PhD, ... and advisor to Spaulding,s Clinical Pharmacology/Pharmacokinetic department.   ... the principles of Clinical Pharmacology and rational drug ...
Cached Medicine Technology:iCyt Unveils Exciting New Flow Cytometry Reagents Utilizing Innovative Fluorochrome Technology 2Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant 2
(Date:7/28/2014)... 2014 Qualis Health, one of ... organizations, has published a complimentary, online toolkit that ... patients and families in infection control. Tested ... the toolkit provides a step-by-step roadmap for implementing ... their families early in a hospital stay. , ...
(Date:7/28/2014)... North America Carotenoids & Antioxidants Market report defines and segments ... and forecast of revenue. This market is estimated to grow ... 2018, at a CAGR of 7.1% from 2013 to 2018. ... & Antioxidants Market report to get an idea of the ... segmentation in the market, and is supported by various tables ...
(Date:7/28/2014)... News) -- People with higher levels of brown fat ... new study suggests. Unlike white fat, which lowers ... insulin sensitivity, blood sugar control and fat-burning metabolism. ... Labros Sidossis, a professor of internal medicine in the ... Medical Branch at Galveston, said in a university ...
(Date:7/28/2014)... decision tree analysis, incorporating Donabedian,s model, is a ... available quality standards, guidelines, recommendations and indicators ... standards for radiation therapy, according to a study ... Practical Radiation Oncology (PRO), the official clinical ... Oncology (ASTRO). , Guidelines, recommendations and indicators may ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A young ... to the all-too-often stories in the media today about ... occur in a matter of minutes in a hot ... to the Office of Emergency Medical Services at NHTSA. ... app for smartphones. Realizing that it’s all too easy ...
Breaking Medicine News(10 mins):Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Healthy 'Brown Fat' May Cut Odds for Obesity, Diabetes 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 2Health News:Two-step decision tree analysis helps inform updates of RT best practices, quality standards 3Health News:'Precious Cargo' App Released to Help Save Babies from the Dangers of Being Accidentally Left Behind in Hot Cars 2
... find themselves in a sticky situation having failed to meet ... lapses in// sticking to rules pertaining to blood safety, ... the total penalty toll against the American Red Cross ... the organization had been fined close to $5.7 million, ...
... amyotrophic lateral sclerosis (ALS), the most common form of ... successful compiling of genetic information on more than 1,000 ... by The Packard Center for ALS Research at Johns ... (NINDS) and the ALS Association, present their initial findings ...
... a lot of other countries, Japan is keen to ... universities, which are currently restricted only to those// who ... of the undergraduate courses like biotechnology and neurosciences to ... prime minister. He is also a professor at the ...
... to the needs of about 1,000 people annually. ... Award for Excellence in Weight// Management 2006 to ... standards that were maintained by this clinic. Glowing ... that offer simple,yet comprehensive solutions to treat obesity. ...
... South Africans are coming forward to seek counseling and ... HIV figures, the Department of Health has reported.// ... have utilized the screening services since 2000, thanks to ... their status. In 2005/06, nearly 1.7-million people underwent the ...
... Welfare stressed the urgency to focus on health and education. ... million people are suffering with HIV/AIDS, and also putting a ... be noted that more than 50 percent of the AIDS ... to be women. Ramadoss expressed how the campaign had slightly ...
Cached Medicine News:Health News:American Red Cross Face Fines After Blood Safety Lapses 2Health News:First International Gene Screen for Typical ALS Is on Track 2
Double Ended Occluders...
49 pinholes, black...
Double Ended Occluders...
Designed to provide occlusion while permitting observation of the eye. Helpful to determine if only one eye is deviating. Approximately 9 inches long....
Medicine Products: